The non-steroidal, selective CYP11A1 inhibitorCYP11A1 inhibitor opevesostat is being studied in two pivotal Phase III trials, OMAHA1 and OMAHA2. Credits: Tada Images/Shutterstock.com
Under the terms of the original agreement, both MSD and Orion had the option to convert the licensing agreement into an exclusive global license for MSD. A wholly exclusive license agreement would give MSD exclusive rights for the global development and commercialisation of opevesostat and other CYP11A1 inhibitorCYP11A1 inhibitor-targeting candidates. Consequently, Orion is now in a position to receive up to $30m for developmental milestones, up to $625m for regulatory milestones, and up to $975m for sales-contingent milestones.
Changing the agreement with MSD allows Orion to allocate its resources to advance other projects while maximising the potential of opevesostat for the treatment of certain prostate cancers and reaping the developmental and commercial benefits of the candidate, Orion president and CEO, Liisa Hurme said in the 1 July press release.
Espoo, Finland-based Orion will also continue to be responsible for the drug manufacturing for the clinical and commercial supply for MSD.
Opevesostat, a non-steroidal, selective CYP11A1 inhibitorCYP11A1 inhibitor, is designed to suppress the production of steroid hormones that may induce the androgen receptor signalling pathway activated in hormone-dependent cancers such as prostate cancer. The treatment is actively being evaluated in two pivotal Phase III studies, OMAHA1 (NCT06136624) and OMAHA2a (NCT06136650).
According to GlobalData’s consensus forecasts, opevesostat is expected to generate global sales of $207m in 2030. GlobalData is the parent company of Pharmaceutical Technology.
OMAHA2a is studying the safety and efficacy of combination therapy compared to Xtandi or Zytica for the treatment of patients with front-line mCRPC who have failed a prior line of an NHA.